IMPLEO MEDICAL, INC.

Impleo Medical is a medical device company developing a minimally invasive injection therapy for Gastroesophageal Reflux Disease (GERD), the most common GI diagnosis affecting over 60 million people in the United States. The company's product is delivered through an outpatient, cost-effective endoscopic procedure injecting a bulking agent into the submucosal tissue of the lower esophageal sphincter. Impleo has completed a pilot clinical study and initiated a pivotal clinical trial aimed at FDA approval. The underlying device platform has been used in over 100,000 patients for non-GERD indications, establishing a significant safety record.